High-dosage fluoride toothpaste for dental root caries

2022-500059-22-01 Therapeutic use (Phase IV) Ended

Start 24 Mar 2023 · End 22 Apr 2024 · Status Ended · 1 EU/EEA countries · 1 sites

Overview

Sponsor-declared trial summary

Phase Therapeutic use (Phase IV)
Status Ended
Participants planned 10
Countries 1
Sites 1

Phenomena and Processes (Fluoride in dental caries control)

To assess to which extent using a high-dosage fluoride toothpaste (5,000 ppm) rather than a normal fluoride toothpaste (1,450 ppm) (establishing a higher concentration of fluoride in the oral environment) will result in more arrest of root caries lesions and hinder more root caries lesion formation (in experimental in …

Key facts

Sponsor
Aarhus University
Participant type
Healthy volunteers
Age range
18-64 years, 65+ years
Gender
Male and Female
Therapeutic area
Phenomena and Processes [G] - Digestive System and Oral Physiological Phenomena [G10]
Trial duration
24 Mar 2023 → 22 Apr 2024
Decision date (initial)
2022-10-31
Transition trial
No
Low-intervention
Yes
Rare-disease indication
No
Vulnerable population
No
Funding sources
Patentmedelsfonden (private Swedish fund) · Tandlægeforeningens Forskningsudvalg (FORSKU) og Forskningsfond (the Danish Dental Association)

Trial design

CTIS Part I — objectives, methods, condition coding

Main objective

Scope: Efficacy

To assess to which extent using a high-dosage fluoride toothpaste (5,000 ppm) rather than a normal fluoride toothpaste (1,450 ppm) (establishing a higher concentration of fluoride in the oral environment) will result in more arrest of root caries lesions and hinder more root caries lesion formation (in experimental in situ specimens), even though no mechanical biofilm-removal takes place.

Conditions and MedDRA coding

Phenomena and Processes (Fluoride in dental caries control)

Regulatory references

EU CT numberTitleSponsor
2022-500059-22-00 High-dosage fluoride toothpaste for root caries control (in situ): a randomized, controlled clinical trial Aarhus University

Eligibility criteria

Principal inclusion / exclusion criteria as submitted by sponsor

Inclusion criteria 2

  1. Age ≥ 18 years old
  2. Lower partial denture

Exclusion criteria 4

  1. Hyposalivation (< 0,5 ml / 5 mins)
  2. Hypersensitivity to any of the components in the trial toothpastes
  3. Pregnancy
  4. Breastfeeding

Endpoints

Primary and secondary outcome measures (English text)

Primary endpoints 1

  1. Mineral loss / uptake in experimental bovine dental root slabs (in situ)

Secondary endpoints 1

  1. The fluoride concentration in saliva and biofilm (on the bovine dental root slabs)

Investigational products

Investigational medicinal products (IMPs), comparators, placebo, auxiliary

Test 1

Duraphat, tandpasta

PRD489292 · Product

Active substance
Fluoride
Pharmaceutical form
TOOTHPASTE
Route of administration
ORAL USE
Max daily dose
3 g gram(s)
Max total dose
99 g gram(s)
Max treatment duration
99 Month(s)
Authorisation status
Authorised
ATC code
A01AA01 — SODIUM FLUORIDE
Marketing authorisation
34657
MA holder
COLGATE PALMOLIVE A/S
MA country
Denmark
Paediatric formulation
No
Orphan designation
No
Modified vs. Marketing Authorisation
No

Placebo 1

Toothpaste (cosmetic product), fluoride concentration: 1,450 ppm

N/A · Product

Other product name
N/A
Pharmaceutical form
N/A
ATC code
N/A — N/A
Marketing authorisation
N/A
MA holder
N/A
MA country
Iceland
Paediatric formulation
No

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

Aarhus University

Sponsor organisation
Aarhus University
Address
Vennelyst Boulevard 6
City
Aarhus C
Postcode
8000
Country
Denmark

Scientific contact point

Organisation
Aarhus University
Contact name
Primary investigator

Public contact point

Organisation
Aarhus University
Contact name
Primary investigator

Locations

1 EU/EEA country · 1 investigational sites

By country

CountryMS statusPlanned subjectsSites
Denmark Ended 10 1
Rest of world 0

Investigational sites

Denmark

1 site · Ended
Aarhus University
Dentistry and Oral Health, Vennelyst Boulevard 4, 8000, Aarhus C

Country notifications

Trial-start, recruitment-start, end and early-termination notifications submitted per Member State

Country Trial startTrial end Recruitment startRecruitment end Early termination
Denmark 2023-03-24 2024-04-22 2023-05-11 2023-11-16

Results and documents

Annex IV summary of results, Annex V layperson summary, and all documents registered in CTIS for this trial

Summary of results Art. 37(4) CTR

TitleSubmission dateStatusType
Preliminary summary results
SUM-75552
2025-03-19T14:32:04 Submitted Summary of Results

Layperson summary Annex V

TitleSubmission dateStatusType
Preliminary layman summary 2025-03-19T14:34:41 Submitted Laypersons Summary of Results

Documents 2 files

Public protocol annexes, IB summaries, regulatory submissions and post-authorisation documents registered in CTIS.

TypeTitleVersion
Laypersons summary of results (for publication) Layman_summary__2022_500059_22_01_dated19032025 1
Summary of results (for publication) Results_summary_2022_500059_22_01_dated19032025 1

Application history

3 submissions — initial application plus substantial / non-substantial modifications

#TypeCodeSubmittedReference MSConclusionDecision date
1 INITIAL IN 2022-08-03 Denmark Acceptable
2022-10-31
2022-10-31
2 NON SUBSTANTIAL MODIFICATION NSM-5 2023-11-17 Denmark Acceptable
2022-10-31
2023-11-17
3 SUBSTANTIAL MODIFICATION SM-1 2023-12-15 Denmark Acceptable
2024-01-05
2024-01-07